Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Ab-Biotics","sponsor":"Zambon Group SpA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Covid-19. A Probiotic Formula Reduces Symptom Duration and Viral Load, Increases Antibodies, and Improves Remission Rate Among Patients With Mild Symptoms","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"SPAIN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Ab-Biotics

    Menu

    Ab-Biotics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Ab-Biotics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Spain
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Covid-19. A Probiotic Formula Reduces Symptom Duration and Viral Load, Increases Antibodies, and Improves Remission Rate Among Patients With Mild Symptoms

              Details:

              AB21 (KABP022) formula, consisting of four specific probiotic strains, produces significant positive effects in COVID-19 outpatients, with benefits on remission rate, symptom duration and viral load.

              Lead Product(s): KABP022,KABP023,KABP033

              Therapeutic Area: Infections and Infectious Diseases Product Name: AB21

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: Zambon Group SpA

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 21, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY